Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Disease improvement · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
455 questions · 462 findings · 28 reviews
No studies found 107 · 23.2%GRADE not reported 92 · 19.9%Very low 98 · 21.2%Low 75 · 16.2%Moderate 68 · 14.7%High 22 · 4.8%
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Remission · people with active UC
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) may leads to higher remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
- RR 1.22 [1.01, 1.47]1 study · 84 participantsLow
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Disease improvement · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Minor adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Serious adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Withdrawals due to adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Probiotics vs placebo
Disease improvement (based on clinical scores) · people with active UC
Probiotics may leads to higher disease improvement (based on clinical scores) compared with placebo (low certainty).
1 finding from 1 review
- RR 2.29 [1.13, 4.63]2 studies · 54 participantsLow
Probiotics vs placebo
Minor adverse events · people with active UC
It is very uncertain whether probiotics changes minor adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.04 [0.42, 2.59]7 studies · 520 participantsVery low
Probiotics vs placebo
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 0.09 [0.01, 1.66]7 studies · 526 participantsVery low
Probiotics vs placebo
Withdrawals due to adverse events · people with active UC
Probiotics showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.85 [0.42, 1.72]4 studies · 401 participantsLow
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Clinical remission · people with active UC
Probiotics showed no clear difference in clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
- RR 0.92 [0.73, 1.16]1 study · 116 participantsLow
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Minor adverse events · people with active UC
It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
- RR 12 studies · 192 participantsVery low
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
- RR 0.21 [0.01, 4.22]1 study · 116 participantsVery low
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Withdrawals due to adverse events · people with active UC
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
- RR 0.21 [0.01, 4.22]1 study · 116 participantsVery low
Probiotics vs placebo
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes clinical relapse (12 to 52 weeks) compared with placebo (very low certainty).
1 finding from 1 review
- Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.87 [0.63, 1.18]4 studies · 361 participantsVery low
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
- Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 1.02 [0.46, 2.25]1 study · 222 participantsVery low
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
- Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Health‐related quality of life (52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
- Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 222 participantsLow
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
- Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 1.11 [0.66, 1.87]2 studies · 242 participantsVery low
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
1 finding from 1 review
- Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 1.05 [0.89, 1.24]1 study · 122 participantsLow